NIH R01 · 2024
ABSTRACT Mycobacterium abscessus (Mab) accounts for most pulmonary infections caused by fast-growing non- tuberculous mycobacteria (NTM). Incidence and prevalence rates are increasing throughout the developed world, there is currently no reliable cure for Mab lung disease, and the drug development pipeline is limited to repurposed and largely underperforming antibiotics. During the previous funding cycle, we have leveraged 2 decades of chemical matter, tools and concepts developed by the TB community to build an attractive anti-Mab drug discovery portfolio of 8 novel advanced lead compounds with demonstrated efficacy in an immunocompromised Mab mouse model. Meanwhile, we have optimized an…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.